SRC and cancer: Moreover, these radiotracers appear to have significant potential to assess response to treatment with a range of classes of anti-cancer drugs (e.g., ERK, Src and VEGFR2 inhibitors) by providing early guidance on the efficacy of these agents in clinical studies.